JAMP LAMIVUDINE 300 MG
LAMIVUDINE : 300 MG · DIN 02507129 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP LAMIVUDINE?
JAMP LAMIVUDINE 300 MG contains LAMIVUDINE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02507129, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Mar-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02507129 |
|---|---|
| Brand name | JAMP LAMIVUDINE |
| Generic / active ingredient | LAMIVUDINE : 300 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AF05 LAMIVUDINE |
| AHFS class | 08:18.08.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Mar-2021 |
| Original market date | 2021-03-16 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J05AF05 LAMIVUDINE. 9 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 3TC | 10 MG | SOLUTION | VIIV HEALTHCARE ULC | MARKETED | DIN 02192691 |
| 3TC | 150 MG | TABLET | VIIV HEALTHCARE ULC | MARKETED | DIN 02192683 |
| 3TC | 300 MG | TABLET | VIIV HEALTHCARE ULC | MARKETED | DIN 02247825 |
| APO-LAMIVUDINE | 150 MG | TABLET | APOTEX INC | MARKETED | DIN 02369052 |
| APO-LAMIVUDINE | 300 MG | TABLET | APOTEX INC | MARKETED | DIN 02369060 |
| APO-LAMIVUDINE HBV | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02393239 |
| JAMP LAMIVUDINE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02507110 |
| JAMP LAMIVUDINE HBV | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02512467 |
| AURO-LAMIVUDINE | 150 MG | TABLET | AURO PHARMA INC | CANCELLED POST MARKET | DIN 02410575 |
| AURO-LAMIVUDINE | 300 MG | TABLET | AURO PHARMA INC | CANCELLED POST MARKET | DIN 02410567 |
Who else supplies LAMIVUDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LAMIVUDINE appears in 32 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.